How to Build NDA/BLA Infrastructure Without Overbuilding
- Feb 11
- 3 min read
For small and startup pharma and biotech companies, few phrases trigger more anxiety than “NDA/BLA infrastructure.” It’s often interpreted as a warning sign that heavy systems, big-pharma processes, and large teams are inevitable—and imminent.
In reality, most Phase 2/3 companies already have more infrastructure in place than they realize. If you’re running an IND, you’re already operating in an eCTD environment, managing submissions, responding to FDA feedback, and maintaining regulatory records.
The real question as you move toward NDA/BLA isn’t whether you need infrastructure—it’s whether what you have can scale to the volume, velocity, and submission types that come next.
In this fifth post of our NDA/BLA series, we’ll break down how to build NDA/BLA infrastructure intentionally—without overbuilding, overspending, or slowing your team down.
The Biggest Myth: “We’ll Need All-New NDA/BLA Infrastructure”
One of the most common misconceptions we hear is that NDA/BLA preparation requires a fundamentally different publishing or regulatory operations setup than IND-stage development.
In practice, that’s rarely true.
IND-stage sponsors already:
Publish and manage eCTD submissions
Handle lifecycle operations and validation
Maintain controlled regulatory documentation
Coordinate cross-functional inputs under deadline
Those foundations don’t disappear at NDA/BLA. What changes is scale.
What Actually Changes as You Approach NDA/BLA
Rather than a tooling problem, the IND → NDA/BLA transition is usually a capacity and complexity problem. Let's look at the top key shifts in the process.
1. Submission Volume and Concurrency
NDA and BLA programs introduce:
Larger, more complex submissions
Multiple modules moving in parallel
Increased frequency of amendments
Overlapping timelines that stress small teams
Processes that worked well for INDs can start to strain—not because they’re wrong, but because they weren’t designed for this load.
2. New Submission Types Post-Approval
As approval approaches, teams must prepare for submission types that may be entirely new:
Advertising and promotional submissions
Labeling updates
Supplements and post-marketing commitments
Ongoing lifecycle maintenance
These submissions often come fast, with strict timelines and high visibility—making experience and staffing just as critical as systems.
3. Personnel, Not Platforms, Become the Bottleneck
By NDA/BLA stage, most infrastructure challenges trace back to people:
Too few trained regulatory operations resources
Limited experience with NDA/BLA-scale publishing
Knowledge concentrated in a single individual
Scaling infrastructure at this stage is often less about adding tools—and more about adding capacity, redundancy, and clarity of ownership.
What “Right-Sized” Infrastructure Looks Like
Building NDA/BLA infrastructure without overbuilding means focusing on resilience over perfection. That often includes:
Ensuring your existing publishing systems can handle increased volume
Establishing clear submission workflows and handoffs
Documenting processes that currently live in people’s heads
Creating backup coverage so timelines don’t hinge on one person
These steps don’t require a massive overhaul—but they do require intention.
Where Small Teams Get the Biggest Return
For Phase 2/3 sponsors, the highest-impact infrastructure investments are often:
Capacity planning for NDA/BLA and post-approval submission load
Training and onboarding for NDA/BLA-specific submission types
Regulatory operations process clarity, not reinvention
Early coordination between regulatory, clinical, CMC, and quality teams
These investments reduce risk without locking teams into rigid structures too early.
Avoiding the Two Extremes
Most first-time sponsors fall into one of two traps:
Underbuilding, assuming IND-era processes will “just stretch” indefinitely
Overbuilding, adopting big-pharma models that overwhelm small teams
The sweet spot lies in between: evolving what already works, reinforcing it where needed, and adding capacity ahead of known pressure points.
Infrastructure as an Enabler, Not a Constraint
When built thoughtfully, NDA/BLA infrastructure should fade into the background—supporting the program rather than slowing it down. The goal isn’t to look ready. It’s to be ready—for the submissions, questions, and responsibilities that come with success.
Looking Ahead in the Series
In the next post, we’ll explore early mistakes that create NDA/BLA pain later—and how to spot them before they become expensive. At The Sugar Water Operations Team, we help sponsors scale regulatory operations realistically—building on IND foundations, planning for post-approval realities, and adding only what truly supports success. Ready to talk? Contact us, or stay up to date by following us on LinkedIn and signing up for our newsletter.